Centers of Excellence
The Latest Research on mHSPC
From the Desk of the Editor: Blink and You’ll Miss Something - Incorporating the Advances in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) into Clinical Practice
The approach to the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has undergone a dramatic transformation over the last few years. This is probably most surprising because of the lack of therapeutic developments for those patients for several decades prior.
Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She is a clinician and physician investigator specializing is investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.